Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells

This publication has 34 references indexed in Scilit:

• A HMG-CoA Reductase Inhibitor Improved Regression of Atherosclerosis in the Rabbit Aorta without Affecting Serum Lipid Levels: Possible Relevance of Up-Regulation of Endothelial NO Synthase mRNA
  Biochemical and Biophysical Research Communications, 1999
• Effect of cerivastatin sodium, a new inhibitor of HMG‐CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
  British Journal of Pharmacology, 1999
• Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels
  Circulation, 1998
• Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation
  Oncogene, 1998
• Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
  Journal of Clinical Investigation, 1998
• Comparison of Bezafibrate Versus Lovastatin or Lowering Plasma Insulin, Fibrinogen, and Plasminogen Activator Inhibitor-1 Concentrations in Hyperlipemic Heart Transplant Patients
  The American Journal of Cardiology, 1997
• Vastatins Inhibit Tissue Factor in Cultured Human Macrophages
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
• Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli.
  Circulation, 1994
• The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
  New England Journal of Medicine, 1992
• Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells.
  The Journal of cell biology, 1991